NanoBio, Merck deal

NanoBio granted Merck exclusive, worldwide rights to NanoBio's nanoemulsion-based adjuvant technology for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive, worldwide rights for use in an intranasal seasonal influenza and/or universal seasonal influenza vaccine. NanoBio will receive an upfront payment and is eligible to receive milestones and royalties. ...